Research suggests that saffron may offer anxiety-relieving benefits, with a 2018 systematic review of randomized controlled trials finding that saffron produced outcomes roughly comparable to standard anti-anxiety medications while generally causing fewer side effects, leading the authors to characterize it as having a favorable risk-benefit profile. A separate 2023 animal study examined a saffron-derived compound called transcrocetin meglumine salt and found it reduced anxiety-related behavior in mice alongside its effects on inflammatory pain, though findings from animal research cannot be directly applied to humans. The available human evidence, while encouraging, is based on a relatively small number of trials, and the systematic review's authors emphasized that larger and more rigorously designed clinical trials are needed before formal recommendations can be made. Overall, the research direction is generally supportive but preliminary, and readers should consider that much of the foundational work still relies on small studies or animal models.
Citations from PubMed and preprint sources. Match score (0-100) reflects automated search ranking, not clinical appraisal.
| Title | Type | Year | Direction | Match |
|---|---|---|---|---|
| Herbal medicine for depression and anxiety: A systematic review with assessme... | Systematic review | 2018 | Supports | 72 |
| Transcrocetin Meglumine Salt Inhibits Spinal Glial Cell-Mediated Proinflammat... | Other | 2023 | Mixed | 67 |